All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given.  View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia

By Cynthia Umukoro

Share:

Aug 24, 2016


The ability to predict therapeutic response is essential for improving the care of patients with acute myeloid leukemia (AML).  M.Luskin et al. developed a methylation-based risk score (M-score) for AML using random forest classification and demonstrated the association between M-score and overall survival (OS) on a limited cohort of AML patients.

For this current study M.Luskin et al. of UPENN,  investigated whether the M-score could independently predict clinical outcome in 166 patients from UPENN with de novo AML treated with intensive induction chemotherapy controlling for other prognostic markers. Their findings were published in JCI Insight in June 2016.

Here are the key findings from their study:

  • In response to 1 or 2 cycles of induction chemotherapy, 71% achieved complete remission (CR) and 38% were alive at 2 years 
  • The mean M-score for surviving patients was significantly lower than for deceased patients (81.8; 95% CI, 74.3–89.2, vs. 99.5; 95% CI 93.2–105.8, P=0.0005,.
  • Patients achieving CR also had a lower mean M-score compared with those who failed to achieve CR (86.8; 95% CI, 81.3–92.4, vs. 105.8; 95% CI, 96.5–115.0, P=0.0005).
  • A univariate Cox survival analysis demonstrated that a 10-unit increase in the M-score was associated with a 10% increase in the hazard of death (P <0.0001 and a 20% increase in the odds of failing to achieve CR
  • M-score was associated with cytogenetic risk; those with favorable cytogenetics had a lower mean M-score than both the intermediate and unfavorable cytogenetics (P<0.0001 and P=0.001, respectively)
  • There was no difference in mean M-score between intermediate and unfavorable groups (P1.0).
  • The M-score classifier identified groups with a different outcome, regardless of whether patients did or did not receive allogeneic stem cell transplant (log-rank P=0.01 and P<0.00001, respectively).

In summary, this study has demonstrated some promising results regarding the robustness of the M-score as a prognostic tool. As correlations between the median M-score and OS and the median M-score and CR were observed.

 

References

More about...

Your opinion matters

How important to you is the turnaround time for genetic testing in guiding your initial treatment decisions?